A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Oral Enteric Fever Vaccine (ZH9 + ZH9PA) in Healthy Participants
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Bivalent typhoid vaccine Prokarium (Primary)
- Indications Typhoid
- Focus Adverse reactions; First in man
- Sponsors Prokarium
Most Recent Events
- 10 Mar 2021 Status changed from recruiting to completed.
- 15 Apr 2020 Status changed from planning to recruiting.
- 26 Nov 2019 According to a Prokarium media release, the company anticipates dosing of the first subject to begin in the first quarter of 2020.